Sunday 18 October 2026
Export IMRX’s income statement to Excel — free account
Immuneering Corporation
IMRX Healthcare Biotechnology
Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.59
0.05
−1.37%
Follow IMRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(43.75%) | (43.12%) | (43.84%) | (52.15%) | |
| (40.37%) | (39.36%) | (41.01%) | (47.31%) | ||
ROIC |
(9,705.65%) | (81.29%) | (74.29%) | (97.14%) | |
Return on Tangible Assets |
(28.35%) | (33.53%) | (34.59%) | (37.99%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.26) | (1.03) | (0.77) | (0.88) | |
Free Cash Flow |
(50.04) | (45.49) | (49.91) | (56.99) | |
Capital Expenditures |
(0.03) | (0.14) | (0.21) | (0.24) | |
| Other line items | |||||
Cash ROIC |
(10.99%) | (11.62%) | (13.74%) | (16.73%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.81 | 0.91 | 0.99 | |
Depreciation/Fixed assets |
0.72 | 0.58 | 0.15 | (0.49) | |
Capex/Depreciation |
(0.04) | (0.26) | (1.49) | 0.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.26) | (1.03) | (0.77) | (0.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates